99 Flake | Jotup

Unprecedented Psoriasis Results: 92% Success Rate with Steroid-Free ARCTIVA™ Cream

Retrieved on:

Monday, June 12, 2023

Cream, Psoriasis, 99 Flake, Vitamin, Skin, FDA, Salicylic acid, Red, Irritation, Cosmetics, Sulfur, Amazon

It showed that 92% of users experienced calmer, more moisturized skin and significantly reduced psoriasis symptoms using the proprietary cream.

Key Points:

It showed that 92% of users experienced calmer, more moisturized skin and significantly reduced psoriasis symptoms using the proprietary cream.
ARCTIVA Psoriasis Cream is a steroid-free, medicated formulation which features 2% salicylic acid as an FDA-approved active ingredient.
"Our proprietary ARCTIVA Psoriasis Cream has been formulated with essential ingredients to provide deep relief and hydration to psoriasis sufferers," said Vic Peroni, chief operating officer of ARCTIVA Wellness.
The ARCTIVA™ Psoriasis Cream study revealed that users experienced significant improvements:
Within two weeks, 81% had less flakes and sloughing, while 89% experienced less itching
ARCTIVA Psoriasis Cream is manufactured in the U.S. and comes with a 60-day money-back guarantee.

New Eczema Study: 91% of Panelists See Relief Using Steroid-Free ARCTIVA™ Formulation

Retrieved on:

Monday, May 1, 2023

Cream, 99 Flake, Dermatitis, Peroni, Vitamin, Patient, FDA, Red, Sulfur, Cosmetics, Dietary supplement, Amazon

The revolutionary new skincare product joins the market as one of the most effective steroid-free treatments for eczema and dermatitis.

Key Points:

The revolutionary new skincare product joins the market as one of the most effective steroid-free treatments for eczema and dermatitis.
ARCTIVA Eczema Cream is the only product line on the market that features breakthrough HYDROSURF™ glycolipid technology—a powerful blend of fermented ingredients with origins from Antarctica.
Within the first seven days of the eczema panel, participants experienced significant relief of itching, redness and flaking.
"The longer people used the ARCTIVA Eczema Cream, the more relief they experienced," said Peroni.

EPI Health and MC2 Therapeutics Announce Wynzora® Cream (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%) now covered on Express Scripts National Preferred Formulary

Retrieved on:

Tuesday, November 9, 2021

CHARLESTON, S.C. and COPENHAGEN, Denmark, Nov. 9, 2021 /PRNewswire/ -- EPI Health, LLC, a specialty pharmaceutical company committed to delivering innovative prescription therapies to dermatologists and MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard within topical therapies for plaque psoriasis today announced that Express Scripts, a large pharmacy benefit manager (PBM) has provided access to Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) for once-daily topical treatment of plaque psoriasis in adults 18 years of age or older on its National Preferred, National Preferred Flex, High Performance, and Basic formularies.

Key Points:

With a reported prevalence of 2-4% of the population, psoriasis constitutes aserious health problem with more than 100 million individuals affected worldwide.
Wynzora Cream is based on PAD Technology, which uniquely enables stability of both calcipotriene and betamethasone dipropionate in aconvenient-to-use aqueous formulation.
Inthe phase 3 trials conducted at multiple sites in the US and the EU, Wynzora Cream has demonstratedauniquecombinationof compellingclinicalefficacy, afavorablesafetyprofileandhighconvenience.
Wynzora (calcipotriene and betamethasone dipropionate) Cream is a prescription medicine indicatedforthetopical treatmentofplaquepsoriasisin patients 18years ofageandolder.